Research programme: cyclin-dependent kinase inhibitors - AmgenAlternative Names: Compound '277; Cyclin-dependent kinase inhibitors research programme - Amgen
Latest Information Update: 05 Sep 2008
At a glance
- Originator Amgen
- Class Small molecules
- Mechanism of Action Cyclin-dependent kinase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 05 Sep 2008 No development reported - Preclinical for Cancer in USA (unspecified route)
- 18 Oct 2004 Preclinical trials in Cancer in USA (unspecified route)